Triggered Drug Release from an Antibody–Drug Conjugate Using Fast “Click-to-Release” Chemistry in Mice

Rossin, Raffaella; Duijnhoven, Sander M.J. van; Hoeve, Wolter ten; Janssen, Henk M.; Kleijn, Laurens H. J.; Hoeben, Freek J. M.; Versteegen, Ron M.; Robillard, Marc S.

doi:10.1021/acs.bioconjchem.6b00231

Cited by 182 publications

(239 citation statements)

References 31 publications

(106 reference statements)

Supporting

Mentioning

234

Contrasting

Order By: Relevance

“…157 Finally, Rossin et al very recently expanded the scope of this methodology even further by harnessing the newly developed IEDDA pyridazine elimination reaction to trigger the selective in vivo cleavage of tumor-bound antibody-drug conjugates (ADCs). 158 This innovative “click-to-release” approach has the potential to add a powerful new tool to the arsenal of ADC therapies.…”

Section: In Vivo Pretargetingmentioning

confidence: 99%

Click Chemistry and Radiochemistry: The First 10 Years

Meyer¹,

et al. 2016

View full text Add to dashboard Cite

The advent of click chemistry has had a profound influence on almost all branches of chemical science. This is particularly true of radiochemistry and the synthesis of agents for positron emission tomography (PET), single photon emission computed tomography (SPECT), and targeted radiotherapy. The selectivity, ease, rapidity, and modularity of click ligations make them nearly ideally suited for the construction of radiotracers, a process that often involves working with biomolecules in aqueous conditions with inexorably decaying radioisotopes. In the following pages, our goal is to provide a broad overview of the first 10 years of research at the intersection of click chemistry and radiochemistry. The discussion will focus on four areas that we believe underscore the critical advantages provided by click chemistry: (i) the use of prosthetic groups for radiolabeling reactions, (ii) the creation of coordination scaffolds for radiometals, (iii) the site-specific radiolabeling of proteins and peptides, and (iv) the development of strategies for in vivo pretargeting. Particular emphasis will be placed on the four most prevalent click reactions—the Cu-catalyzed azide-alkyne cycloaddition (CuAAC), the strainpromoted azide-alkyne cycloaddition (SPAAC), the inverse electron demand Diels-Alder reaction (IEDDA), and the Staudinger ligation—although less well-known click ligations will be discussed as well. Ultimately, it is our hope that this review will not only serve to educate readers but will also act as a springboard, inspiring synthetic chemists and radiochemists alike to harness click chemistry in even more innovative and ambitious ways as we embark upon the second decade of this fruitful collaboration.

show abstract

Section: In Vivo Pretargetingmentioning

confidence: 99%

Click Chemistry and Radiochemistry: The First 10 Years

Meyer¹,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This model showed enhanced tumor uptake, higher in vivo stability, and resulted in effective release and tumor retention of the drug due to the selective reactivity with tetrazine. [97] There have been other significant recent reports using the bio-orthogonal reaction between trans-cyclooctene and tetrazine, and this approach is rapidly becoming popularized for molecular imaging and cell-based diagnostics, owing to the rapid reaction kinetics and enhanced selectivity. To aid pretargeting, trans-cyclooctene is usually attached to the lysine [49] www.advancedsciencenews.com www.advhealthmat.de residues of mAbs through the standard amine reaction.…”

Section: Wwwadvancedsciencenewscom Wwwadvhealthmatdementioning

confidence: 99%

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

Sivaram

Wardiana

Howard

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Targeted nanomedicines have significantly changed the way new therapeutics are designed to treat disease. Central to successful therapeutics is the ability to control the dynamics of protein–nanomaterial interactions to enhance the therapeutic effect of the nanomedicine. The aim of this review is to illustrate the diversity and versatility of the conjugation approaches involved in the synthesis of antibody–nanoparticle conjugates, and highlight significant new advances in the field of bioconjugation. Such nanomedicines have found utility as both advanced therapeutic agents, as well as more complex imaging contrast agents that can provide both anatomical and functional information of diseased tissue. While such conjugates show significant promise as next generation targeted nanomedicines, it is recognized that there are in fact no clinically approved targeted therapeutics on the market. This fact is reflected upon within this review, and attempts are made to draw some reasoning from the complexities associated with the bioconjugation chemistry approaches that are typically utilized. Present trends, as well as future directions of next generation targeted nanomedicines are also discussed.

show abstract

“…Chemical [70], near-infrared light [71] and tumor microenvironment-triggered payload release strategies have also shown promising results. There is probably no universal conjugate-linkage strategy optimal for all antibody-drug conjugates.…”

Section: Introductionmentioning

confidence: 99%

DNA damaging agent-based antibody-drug conjugates for cancer therapy

2018

Antibody Therapeutics

View full text Add to dashboard Cite

Currently, four antibody-drug conjugates (ADCs) are approved by the Food and Drug Administration or the European Medicine Agency to treat cancer patients. More than 60 ADCs are in clinical development for cancer therapy. More than 60% of ADCs in clinical trials employ microtubule inhibitors as their payloads. A better understanding of payloads other than microtubule inhibitors, especially DNA-damaging agents, is important for further development of ADCs. In this review, we highlight an emerging trend of using DNA-damaging agents as payloads for ADCs. This review summarizes recent advances in our understanding gained from ongoing clinical studies; it will help to define the utility of DNA-damaging payloads for ADCs as cancer therapeutics. Future directions of the development of ADCs are also discussed, focusing on targeting drug resistance and combination treatment with immunotherapy.

show abstract

Triggered Drug Release from an Antibody–Drug Conjugate Using Fast “Click-to-Release” Chemistry in Mice

Cited by 182 publications

References 31 publications

Click Chemistry and Radiochemistry: The First 10 Years

Click Chemistry and Radiochemistry: The First 10 Years

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

DNA damaging agent-based antibody-drug conjugates for cancer therapy

Contact Info

Product

Resources

About